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Summary Pre- and post-treatment specimens from 47 patients with hormone resistant prostatic carcinoma
were compared with each other regarding histological grade and immunoreactivity for p53 protein, neuron
specific enolase and c-erbB-2 protein. Significantly more specimens expressed a high malignancy grade when
the tumour had become hormone resistant than at the time of initial diagnosis (Gleason P:<0.0001, WHO
P:0.0003). p53 protein immunoreactivity increased significantly with disease progression (P:0.006), while tissue
PSA immunoreactivity was reduced in post-treatment specimens (P:0.011). p53 protein expression did not
correlate with histological grade or PSA expression and seems to be an independent parameter which
participates late in the neoplastic transformation. Thirty-two percent of the tumours were neuron specific
enolase positive, but this parameter did not correlate with development of hormone resistance. c-erbB-2
protein reactivity was not recognised.
Prostatic adenocarcinoma which accounts for more than
20% of all malignant neoplasms in males in Norway, exhibits
great variation in clinical and biological behaviour (Gleason,
1974; Murphy et al., 1982; Epstein et al., 1986; Johansson et
al., 1989; Whitmore Jr. et al., 1991; Smith Jr. et al., 1991).
The most commonly used prognostic parameters in untreated
patients are histological grade, T category of the primary
tumour as defined by UICC (UICC, 1978), extent of metasta-
tic tumour burden, serum testosterone level and serum pros-
tate specific antigen level (PSA). In hormone resistant pros-
tatic cancer, factors such as the patient's performance status
and serum alkaline phosphatase level seem to be of prognos-
tic significance (Berry et al., 1979; Mulders et al., 1990;
Matzkin et al., 1992).
Immunohistochemical demonstration of neuroendocrine
differentiation (di Sant 'Agnese & de Mesy Jensen, 1987;
Cohen et al., 1991), c-erbB-2 protein (Gullick et al., 1991;
Reilly et al., 1991; Hale et al., 1992), p53 protein (Porter et
al., 1992) and PSA (Hammond et al., 1989; Bazinet et al.,
1992) have also been related to tumour growth.
In order to increase our understanding of the biological
changes associated with the development of therapy resis-
tance, we examined some of the above mentioned parameters
in prostatic cancer specimens obtained before hormone treat-
ment and in comparable specimens achieved when the patient
had developed a hormone resistant malignancy.
Material and methods
Clinical material
Forty-seven patients with prostatic cancer were identified in
whom at least one tissue specimen had been obtained before
start of hormone treatment and one biopsy when the tumour
had progressed despite androgen suppressive therapy, achiev-
ed either by surgical or medical castration. Patient details are
shown in Table I which also reflects the considerable hetero-
geneity of the clinical parameters. When multiple biopsies
were available, the first pre-treatment and the last post-
treatment biopsy were always retrieved. Only biopsies from
primary tumours were selected, and 75 of the specimens were
obtained by transurethral resection (TUR), 17 were core
biopsies (CB) and one was obtained by transvesical resection
(TV). A tumour was characterised as hormone resistant when
the patient had clinical progression after at least 3 months of
androgen suppression.
All patients had been referred to The Norwegian Radium
Hospital (NRH) for palliative treatment between 1981 and
1992. At that time the patients underwent clinical, radio-
logical and biochemical examinations including examination
of serum PSA (from 1986) (Wehre et al., 1992). Only limited
information is, however, available about the extent of the
disease at the time of diagnosis.
Light microscopy
The tissue samples were fixed in buffered 4% formalin and
embedded in paraffin. FivetLm sections were cut and stained
with haematoxylin and eosin for light microscopy. The
tumours were graded according to Gleason's (Gleason, 1974)
and WHO's (Mostofi et al., 1980) classification systems.
Gleason grades were grouped as follows: grades 2-4 (group
1), grades 5-7 (group 2) and grades 8-10 (group 3).
Immunohistochemistry
Paraffin-embedded material was prepared by applying the
avidin-biotin-peroxidase complex (ABC) method (Hsu et al.,
1981). After removal of paraffin, the sections were treated for
30min with 0.3% hydrogen peroxide in methanol to block
endogenous peroxidase, followed by 20 min incubation with
non-reactive serum diluted 1:75 om 0.01M phosphate buffer-
ed saline (pH 7.4) containing 5% bovine serum albumin
(BSA) to eliminate non-specific staining. The sections were
then incubated at 4°C overnight with the primary antibodies
raised against c-erbB-2 protein (monoclonal antibody diluted
1:40 (NCL CB1 1 Novocastra, UK)), NSE (monoclonal anti-
body diluted 1:700 (Dakopatts)), p53 protein (Polyclonal
antibody diluted 1:300 (Novocastra)) and PSA (monoclonal
Table I Patient details
Age at diagnosis (years) 66a (47-8O)b
M category: MO 12
Ml 14
MX 21
Hormone treatment: orchiectomy 41
oestrogens 1
LH-RH analogues 5
Interval between diagnosis and hormonal 3a (0 74)b
treatment (months)
Interval between initial diagnosis and evaluated oa (O-32)b
pre-treatment biopsy (weeks)
Interval between start of hormone treatment and gla (15-529)b
evaluated post-treatment biopsy (weeks)
Status at last observation: Alive 12
Dead 35
aMedian value; bRange.
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antibody diluted 1:40 (Dako n750)), followed by 30min
incubation with a 1:200 dilution of the biotin labelled secon-
dary antibody and a 60min incubation with ABC (10iLg
ml-I avidin and 2.5jg ml ' biotin-labelled peroxidase). The
tissues were stained for 5 min with 0.05% 3'3 diaminoben-
zidinetetrahydrochloride freshly prepared in 0.05% tris buffer
(pH 7.6) containing 0.01% hydrogen peroxide and counter-
stained with haematoxylin, dehydrated and mounted.
The immunostained sections were examined independently
by two pathologists (A.B., J.M.N.). Localisation of the
immunostaining in relation to cellular morphology was
noted, and the fraction of immunoreactive tumour cells was
semiquantitatively graded from 0 to + + + in each sec-
tion.
Control studies included relevant positive controls, the use
of IgG of the same fraction as the primary antibody or
non-reactive serum as first layer. The immunoreactivity was
checked with an absorption control adding antigen to the
primary antibody prior to incubation. All controls gave satis-
factory results.
Statistics
All statistical calculations were performed in the PC program
'Medlog'. The following tests were used: Fisher exact proba-
bility test, Chi-squared test. The probability of survival was
calculated by the Kaplan Meyer method and survival differ-
ences were assessed by the log rank test. P-values <0.05
were regarded as statistically significant.
Results
Grade
Using both the Gleason and the WHO grading system,
significantly more specimens with a high histological grade
were found among the post-treatment specimens than among
the pre-treatment biopsies (Gleason: P<0.0001, WHO:
P:0.003) (Table II). In 22 of the 47 patients the tumour was
more undifferentiated in post-treatment specimens (Table
IIIa), while the tumour grade remained unchanged in 25
patients including the ten patients with Gleason grade 8-10
at the time of diagnosis. Undifferentiated carcinomas as
defined by the WHO system were not seen.
Table II Pre- and post-treatment tissue specimens from 47 patients
with therapy resistant carcinomas of the prostate. A: WHO and
Gleason grade. B: Immunostaining with p53 protein, PSA and
NSE
A: Pre-treatment Post-treatment
WHO 1 5 1
WHO 2 20 8
WHO 3 22 38
P: 0.003
Gleason 2-4 4 1
Gleason 5-7 33 15
Gleason 8-10 10 31
P: <0.0001
B:
p53 protein 0/+ 44 35
++ 3 5
+++ 0 7
P: 0.006
Tissue PSA 0/+ 9 17
++ 13 19
+++ 25 11
P: 0.011
NSE 0 35 29
+ 6 12
++ 5 5
+++ 1
P: 0.46
Table III Outcome ofthe individual patient regarding Gleason grade,
p53 protein expression and tissue PSA reactivity in the pre-treatment
group
Pre-treatment Post-treatment
Gleason grade Gleason grade
no. 2-4 5-7 8-10
2-4: 4 1 1 2
5-7: 33 0 14 19
8-10: 10 0 0 10
pS3 protein p53 protein
no. 0/+ ++ +++
±: 44 35 4 5
++: 3 0 1 2
+++: O 0 0 0
Tissue PSA Tissue PSA
no. 0/+ ++ +++
+: 9 8 1 0
++: 13 5 7 1
+++: 25 4 11 10
pS3 protein
In 44 pre-treatment specimens p53 protein expression was
either absent (0:43) or observed only in a few nuclei (+:1).
Three specimens undoubtedly expressed p53 protein in a
significant number of tumour nuclei (++ +++ +) (Table
IIB, Figure 1). When the malignancy had become hormone
resistant the number of heavily immunostained specimens
(+ ++++ +) increased from 3 to 12, while 35 specimens
were coded as 0 (30) or + (5). The difference in p53
immunostaining between the pre-treatment and the post-
treatment groups was statistically significant (P:0.006). When
analysing specimens from individual patients (Table III), it be-
came clear that 15 out of 47 patients expressed increased p53
protein reactivity in their hormone resistant tumour tissue
and 34 remained unchanged (0:30, +:1, + ++++ :1).
Tissue prostate specific antigen (tissue PSA)
Tissue PSA expression in pre- and post-treatment specimens
is shown in Table IIB. Nine pre-treatment specimens ex-
pressed no or weak PSA staining (0/+) compared to 17
post-treatment specimens. Likewise, the number of specimens
with extensive PSA expression (+ +/+ + +) decreased from
25 in the pre-treatment to 11 in the post-treatment groups.
Figure 1 Poorly differentiated adenocarcinoma with p53 protein
positive tumour nuclei (arrow), 400 x.382 A. BERNER et al.
Twenty patients expressed less PSA reactivity in the post-
treatment specimens. The reactivity remained the same in 25
specimens, and only one expressed more PSA (Table III).
The difference was statistically significant (P:0.011).
Serum prostate specific antigen (serum PSA)
At least one serum PSA measurement was available from
each of 36 patients. Thirty-one serum PSA measurements
were obtained from patients with hormone resistant disease,
and five from patients before hormone therapy. In patients
with tissue PSA coded as 0 or +, the median serum PSA
level with 23jig 1' (range: 2-556) compared to a median
serum PSA level of 41 gLg l-' (range 4-1261) in patients with
tissue reactivity coded as + + or + + + (P:0.144) (Figure
2). Median serum PSA level in patients with Gleason grade
2-7 was 43tgl-' (range: 41-1261) compared to a median
serum PSA level of 24,5jig 1' (range: 17-556) in patients
with Gleason grade 8-10 (Figure 3).
Neuron specific enolase (NSE)
Twelve of the pre-treatment specimens demonstrated positive
immunostaining for NSE as shown in Table IIB (+ :6,
++:5, +++:1), compared to 18 of the post-treatment
specimens (+: 12, + +:5, + + +: 1). The difference was not
statistically significant (P:0.46).
C-erbB-2protein
None of the 94 specimens was c-erbB-2 protein positive.
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Figure 2 Comparison of serum PSA and tissue PSA. 15 speci-
mens with no or weak tissue PSA reactivity (0/+) and 21 speci-
mens with strong tissue PSA reactivity (+ +/+ + +).
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Figure 3 Comparison of serum PSA and Gleason grade. 12
specimens with Gleason grade 2-7 and 24 specimens with
Gleason grade 8-10.
Comparison between parameters
When all 94 specimens were evaluated, there were statistically
significant correlations between the Gleason and the WHO
classification systems (P<0.0001), between tissue PSA and
WHO grade (P:0.0036) and between tissue PSA and Gleason
grade (P:0.0004). There was no correlation between p53
protein and WHO grade (P:0.059) and between p53 protein
and tissue PSA (P:0.064).
Time to progression andsurvival
In this limited and clinically heterogeneous series of patients,
no statistically significant correlations were found between
time to progression or survival and histological grade, tissue
PSA or p53 protein expression.
Discussion
In prostatic cancer patients, grade and stage are the most
used prognostic parameters for the clinicians. Among the
available grading systems Gleason and WHO systems are
presently most used. Our study showed a good correlation
between the grading in the Gleason and in the WHO
classification system (P:<0.0001), despite the reported
tendency of undergrading by the Gleason system (Catalona
et al., 1982; Lange & Narayan, 1983) in small biopsies.
However, only 17 of the 94 specimens in our study were core
biopsies.
A fundamental assumption by Gleason (Gleason, 1977)
was that morphologic grade and growth rate of prostatic
cancer remained unaltered throughout the patient's lifespan.
However, this has been contradicted by Brawn and others
(Brawn, 1983; McNeal et al., 1986; MacNeal et al., 1988a).
McNeal and coworkers (1986, 1988a) examined prostatec-
tomy specimens whereas Brawn (1983) graded repeat TUR
biopsies and found that 65% of his patients showed a higher
malignancy grade with time. Gleason did only include some
occasional re-biopsies in his study. In their studies, Lundberg
and associates (1987), Epstein and coworkers (1986) and
deVere White et al. (1990) and others also used only one
tissue specimen from the individual patient and thus limiting
the validity of these investigations. In our study we have
evaluated pre- and post-treatment specimens from the same
patient, and, like Brawn, we found more often less
differentiated tumour tissue in the repeat specimens.
p53 is a suppressor gene which participates in cell cycle
regulation and growth control (Levine et al., 1991). Most
investigators agree that accumulation of p53 protein to levels
detectable by immunohistochemical methods is caused by an
underlying genetic lesion, most frequently point mutation on
chromosome 17, although stabilisation of wild type p53 pro-
tein has been postulated (Wynford-Thomas, 1992). The wide-
spread occurrence of p53 gene mutations in different types of
tumours suggests that p53 mutation participates in the neo-
plastic transformation of most types of human neoplasia
(Porter et al., 1992). The biological significance of p53 pro-
tein overexpression is not established, but most authors agree
that p53 protein expression arises relatively late in neoplastic
progression and may correlate with increased tumour aggres-
siveness (Porter et al., 1992; Sawan et al., 1992). Isaacs and
coworkers (Isaacs et al., 1991) reported p53 mutations in
prostatic cancer cell lines and one p53 gene mutation has
recently been reported in human prostatic cancer tissue
(Effert et al., 1992). Mellon and coworkers (Mellon et al.,
1992) noticed p53 protein expression in five out of 29 poorly
differentiated prostatic carcinomas. This is in agreement with
our findings. In addition, we observed increased p53 protein
immunoreactivity with progression of the disease (P:0.006),
but the p53 protein staining did not significantly correlate
with any other parameters. Thus, increased p53 protein ex-
pression may be a parameter which rather independently
mirrors tumour progression.
Prostate specific antigen (PSA) is produced both in benign
and in malignant prostatic epithelium, and serum PSA is
a
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widely used as a tumour marker, correlating with tumour
stage and response to treatment (Stamey et al., 1987). In
contrast to benign epithelium, most reports on prostatic
cancer tissue demonstrate heterogeneity in immunostaining
and an apparent correlation between variation in PSA stain-
ability and tumour grade (Hammond et al., 1989; Epstein &
Eggleston, 1984; Feiner & Gonzales, 1986). Reduced PSA
immunoreactivity has been noticed in prostatic intra-
epithelial neoplasia (McNeal et al., 1988b). In a study of pre-
and post-treatment prostatic carcinomas, Vernon and Wil-
liams (Vernon & Williams, 1983) found persistent PSA stain-
ing in all biopsies from 30 patients despite morphological
changes with time, while Grignon and Troster (Grignon &
Troster, 1985) reported reduced PSA reactivity in prostate
cancer specimens from five out of 11 hormonally treated
patients. Qiu and associates (Qiu et al., 1990) demonstrated a
significant decrease in PSA mRNA expression in carcinoma
tissue when compared with benign prostatic epithelium.
Reduced PSA concentrations have also been found in car-
cinoma tissue by biochemical methods (Stege et al., 1990;
Pretlow et al., 1991; Stege et al., 1992). This is in agreement
with our findings. Like Grignon and Troster (1985) but
contrary to Vernon and Williams (1983), we noticed a signifi-
cant decrease in PSA staining in post-treatment specimens
(P:0.01).
In our series the tissue stainability for PSA did not cor-
relate with the individual patients serum PSA. This has also
been noticed by Ersev and coworkers (Ersev et al., 1990).
One possible explanation may be that the PSA reactivity in
tissues is often focal and small biopsies do not reflect the
average PSA expression. Furthermore, there may be large
inter-patient variations in PSA release from the cancer cells
and/or a possible increase in PSA diffusion through abnor-
mal blood vessels, which may explain decreased PSA tissue
concentrations in spite of high serum levels (Stege et al.,
1990; Prethlow et al., 1991). Such discrepancies may change
with time and during hormone treatment (Matzkin et al.,
1992).
Approximately 50% of prostatic cancers contain small
numbers of neuro-endocrine cells (di Sant'Agnese & de Mesy
Jensen, 1987; Cohen et al., 1991) and it has been suggested
that neuro-endocrine differentiation is associated with poor
prognosis, which was not confirmed in our study. However,
contrary to di Sant'Agnese and de Mesy Jensen (1987) who
used a battery of different neuro-endocrine markers and
Cohen and coworkers (1991) who used polyclonal NSE anti-
body and monoclonal chromogranin antibody, we used only
one monoclonal antibody raised against NSE, which may
explain the lower scoring rate (32%) in our series. Neuro-
endocrine differentiation is mostly focal and Cohen and
coworkers (1991) demonstrated that a single needle biopsy
may be inadequate in demonstrating neuro-endocrine differ-
entiation.
Although c-erbB-2 gene amplification has been document-
ed in many different tumours, only a few studies have been
performed on prostatic cancer tissue (McCann et al., 1990;
Ware et al., 1991; Mellon et al., 1992). Like McCann and
associates (1990), we did not observe c-erbB-2 protein expres-
sion in formalin fixed prostatic cancer tissue. Both Ware and
associates (1991) and Mellon and coworkers (1992) used
fresh material and found c-erbB-2 protein expression in 71%
and in 21%, respectively. Ware and associates also compared
formalin fixed and fresh material and found that formalin
fixation significantly reduced the c-erbB-2 protein
immunoreactivity. This is also in agreement with Wright and
coworkers observation in bladder tumours (Wright et al.,
1990).
We conclude that prostatic carcinoma showed a signifi-
cantly dedifferentiation when the malignancy became hor-
mone resistant. These changes are associated with increased
p53 protein expression and decreased PSA immunoreactiv-
ity.
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